Absence of Anti-Glomerular Basement Membrane Antibodies in 200 Patients With Systemic Lupus Erythematosus With or Without Lupus Nephritis: Results of the GOODLUPUS Study.

Date publication

janvier 2020

Journal

Frontiers in immunology

Auteurs

Membres identifiés du Cancéropôle Est :
Pr BONNOTTE Bernard , Pr MARTIN Thierry

Tous les auteurs :
Bourse Chalvon N, Orquevaux P, Giusti D, Gatouillat G, Tabary T, Tonye Libyh M, Chrusciel J, Drame M, Stockton-Bliard G, Amoura Z, Arnaud L, Lorenz HM, Blaison G, Bonnotte B, Magy-Bertrand N, Revuz S, Voll RE, Hinschberger O, Schwarting A, Pham BN, Martin T, Pennaforte JL, Servettaz A

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/33381119

Résumé

Anti-glomerular basement membrane (GBM) antibodies are pathogenic antibodies first detected in renal-limited anti-GBM disease and in Goodpasture disease, the latter characterized by rapidly progressive crescentic glomerulonephritis combined with intra-alveolar hemorrhage. Studies have suggested that anti-GBM antibody positivity may be of interest in lupus nephritis (LN). Moreover, severe anti-GBM vasculitis cases in patients with systemic lupus erythematosus (SLE) have been described in the literature, but few studies have assessed the incidence of anti-GBM antibodies in SLE patients.

Mots clés

Goodpasture disease, anti-GBM antibodies, anti-GBM glomerulonephritis, anti-glomerular basement membrane antibodies, lupus nephritis, systemic lupus erythematosus

Référence

Front Immunol. 2020 ;11:597863